Shares of Aldeyra Therapeutics Inc ALDX, a company focusing on immune-mediated diseases, are primed for further upside, according to a Jefferies analyst.
The Aldeyra Analyst: Kelly Shi initiated coverage of Aldeyra shares with a Buy rating and $24 price target.
The Aldeyra Thesis: Aldeyra's lead asset reproxalap has substantial opportunity in ocular inflammatory dry eye disease and allergic conjunctivitis, Shi said in a Friday initiation note.
With market dominant brands such as Allergan's Restasis and Novartis AG's NVS Xiidra having pitfalls such as slow onset of drug action and a suboptimal patient experience, there is an unmet need in moderate-to-severe dry eye patients on chronic therapies, the analyst said.
Related Link: The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Aldeyra's reproxalap has shown a differentiated product profile to date, suggesting commercial competitiveness if approved, she said.
Two Phase 3 data releases in the first half of 2021 should serve as major catalysts, Shi said.
"Other progress from Aldeyra's immune-disease focused pipeline in rare ocular disorders, autoimmune diseases, oncology, and Covid set up a catalyst-rich 12 mos to offer further upside."
ALDX Price Action: Aldeyra shares gained 5.86% in Friday's session, closing at $6.68.
Related Link: The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.